At the time of writing, Apellis Pharmaceuticals Inc [APLS] stock is trading at $18.51, up 4.75%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The APLS shares have gain 7.12% over the last week, with a monthly amount glided 2.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on May 09, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $52 for it. Previously, BofA Securities downgraded its rating to Neutral on May 09, 2025, and kept the price target unchanged to $23. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $44 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $36 on December 17, 2024. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $31 as its price target on November 21, 2024. RBC Capital Mkts started tracking with a Sector Perform rating for this stock on October 25, 2024, and assigned it a price target of $25. In a note dated October 16, 2024, William Blair initiated an Outperform rating.
For the past year, the stock price of Apellis Pharmaceuticals Inc fluctuated between $16.10 and $43.99. Currently, Wall Street analysts expect the stock to reach $74.5 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $18.51 at the most recent close of the market. An investor can expect a potential return of 302.49% based on the average APLS price forecast.
Analyzing the APLS fundamentals
According to Apellis Pharmaceuticals Inc [NASDAQ:APLS], the company’s sales were 775.84M for trailing twelve months, which represents an -3.21% plunge. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.24%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.0 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Apellis Pharmaceuticals Inc [NASDAQ:APLS] has a current ratio of 4.08. Also, the Quick Ratio is 3.62, while the Cash Ratio stands at 2.01. Considering the valuation of this stock, the price to sales ratio is 3.00, the price to book ratio is 14.16.
Transactions by insiders
Recent insider trading involved Townsend Adam J., Former Officer, that happened on May 12 ’25 when 0.22 million shares were purchased. VP/Chief Accounting Officer, Chopas James George completed a deal on Mar 17 ’25 to sell 183.0 shares. Meanwhile, Officer Chopas James George bought 183.0 shares on Mar 17 ’25.
